Biocon Limited — Investor Meet, 07-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon Limited reported a 4% growth in operating revenue for Q2 FY25, driven by strong performance in biosimilars despite challenges in generics and a decline in Syngene's revenues. Significant highlights include a successful refinancing of long-term debt, reaching industry approvals, and a solid outlook for upcoming product launches in generics and biosimilars, including liraglutide and denosumab. The company aims for accelerated growth in the second half of the fiscal year.